Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sertraline effects in adolescent major depression and dysthymia: A six-month open trial
Autore:
Nixon, MK; Milin, R; Simeon, JG; Cloutier, P; Spenst, W;
Indirizzi:
Childrens Hosp Eastern Ontario, Mental Hlth Patient Serv Unit, Ottawa, ON K1H 8L1, Canada Childrens Hosp Eastern Ontario Ottawa ON Canada K1H 8L1 N K1H 8L1, Canada Royal Ottawa Hosp, Childrens Outpatient Dept, Ottawa, ON K1Z 7K4, Canada Royal Ottawa Hosp Ottawa ON Canada K1Z 7K4 pt, Ottawa, ON K1Z 7K4, Canada
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 11, anno: 2001,
pagine: 131 - 142
SICI:
1044-5463(200122)11:2<131:SEIAMD>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
REUPTAKE INHIBITORS; FLUOXETINE; CHILDHOOD; CHILDREN; DISORDER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Nixon, MK Childrens Hosp Eastern Ontario, Mental Hlth Patient Serv Unit Res, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada Childrens Hosp Eastern Ontario 401 Smyth Rd Ottawa ON Canada K1H 8L1
Citazione:
M.K. Nixon et al., "Sertraline effects in adolescent major depression and dysthymia: A six-month open trial", J CH AD PSY, 11(2), 2001, pp. 131-142

Abstract

This 6-month open-label study evaluated the efficacy, tolerability, and safety of sertraline in 21 adolescent psychiatric outpatients, ages 12 to 18 years, diagnosed with major depressive disorder (MDD, n = 13) or dysthymic disorder (DD, n = 8). Both groups showed clinically significant improvements on the Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale, and theClinical Global Impression Scale-Severity (CGI-S). The MDD group showed maximal clinical response (based on the method of last observation carried forward) on the HAM-D and CGI at weeks 12 (76.9%) and 20 (76.9%), respectively. Response rates were maintained at week 24 with all six MDD study completers (100%) responding to treatment. The DD group achieved maximal response on the HAM-D (100%) and the CGI (75%) at week 6. Response rates in this group did not remain as elevated over time with two out of three (66.7%) DD study completers responding to treatment at week 24. Generally, sertraline was safe and well tolerated. Most adverse events were mild to moderate in severity and resolved with no action taken. Results suggest that sertraline may be efficacious in acute and continuation treatment of MDD in adolescents. DD patients showed evidence of clinical response and improvement, particularly in the acute treatment phase. Incorporating a longer evaluation periodin the study of antidepressant therapy for adolescents with MDD and/or DD is emphasized.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:30:58